commercialization Archives

FACIT and T-CAIREM at the University of Toronto partner to commercialize medical AI

Posted on August 2, 2023 (March 7, 2024) by Ricky

August 2, 2023 – FACIT and T-CAIREM announce partnership to commercialize medical artificial intelligence (AI) innovations. The partners intend to harness both T-CAIREM’s innovative translational research in AI and FACIT’s unique commercialization-venture model to build the next generation of Ontario biotechnology companies. The joint mission will accelerate the benefits of AI research to support patients battling cancer.

From Idea to Start up: FACIT President’s interview with Amanda Lang

Posted on May 1, 2023 (September 15, 2024) by Ricky

May 1, 2023 – Watch FACIT President Dr. David O’Neill’s interview with Amanda Lang, host of Taking Stock on BNN Bloomberg. The episode, titled From Idea to Start up, originally aired on April 28, 2023. This was part of a special series about innovation in Canada and some of the challenges and opportunities. FACIT was featured as a “success

New Innovative Cancer Technology Wins 2023 Falcons’ Fortunes Pitch Competition

Posted on March 31, 2023 (September 25, 2023) by nicole

March 31, 2023 – The winning pitch for the 10th anniversary Falcons’ Fortunes pitch competition and the $100,000 Ernsting Entrepreneurship Award was delivered by Dr. Sumaiyah Rehman, co-founder and CEO of DTPx Therapeutics.

FACIT generates $1.5 billion in follow-on investment

Posted on March 29, 2023 (September 15, 2024) by nicole

March 29, 2023 – FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada.

CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer

Posted on March 23, 2023 (May 8, 2023) by nicole

March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.

FACIT’s Prospects Fund invests in two emerging Ontario diagnostics for colorectal and prostate cancers

Posted on September 16, 2021 (September 13, 2024) by jeremy

September 16, 2021 – September 16, 2021 – Both innovations were previous finalists in FACIT’s 2021 Falcons’ Fortunes pitch competition.

FACIT leads seed round in Nanology Labs

Posted on May 18, 2021 (July 4, 2024) by jeremy

May 18, 2021 – May 18, 2021 – FACIT deploys Ontario First capital, enables rising local start-up to reach critical value inflection point. FACIT has previously supported Nanology, spun out of the University of Toronto, through both its early-stage Prospects Oncology Fund and seed-stage Compass Rose Oncology Fund.

FACIT crowns 2021 winner of Falcons’ Fortunes pitch competition; announces follow-on investment in 2020 winner, Bridge7 Oncology

Posted on February 4, 2021 (July 4, 2024) by jeremy

February 4, 2021 – February 4, 2021 – FACIT’s Prospects Oncology Fund and its annual pitch competition help to advance Ontario oncology innovations.

FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund

Posted on December 10, 2020 (July 4, 2024) by jeremy

December 10, 2020 – December 10, 2020 – The newest recipients of Ontario First seed capital include Dr. Rebecca Laposa of the University of Toronto, as well as London-based start-up Multi-Magnetics Inc.

FACIT recognized with 2020 Venture Capital Regional Impact Award by the Canadian Venture Capital & Private Equity Association (CVCA)

Posted on June 9, 2020 (July 4, 2024) by jeremy

June 9, 2020 – June 9, 2020 – FACIT’s award was specifically related to the 2019 historic US$1B partnership between its portfolio companies, Propellon Therapeutics and Triphase Accelerator, and US pharma giant Celgene (acquired by Bristol-Myers Squibb Company).